Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has formed a partnership with v2vmedtech, Inc. to create a novel heart valve repair device for minimally invasive treatment of mitral and tricuspid valve regurgitation, also known as a leaky valve.
This cutting-edge technology is a valuable addition to Anteris' portfolio, allowing the company to expand into a market adjacent to transcatheter aortic valve replacement (TAVR) - a market expected to reach A$4.1 billion by 2028.
With an underpenetrated market and limited competition, the agreement presents an encouraging opportunity for Anteris to collaborate with reputable physicians and develop a device that can broaden the pool of treatable patients
Looking ahead, the company is confident that this partnership will enable them to bring innovation to the established yet rapidly growing structural heart space.
Market potential
Anteris CEO Wayne Paterson said: “This strategic partnership allows us to tap into our core capabilities of innovation and existing network of physician advisors while broadening our portfolio and entering additional market segments where we can expect significant long-term growth.”
To date, these devices have been developed through physician-led research from New York Presbyterian/Columbia University Hospital, NYC, and utilise a transcatheter edge-to-edge repair method.
The technology complements AVR's portfolio by entering a market adjacent to the transcatheter aortic valve replacement (TAVR) market in which the company remains focused on developing the DurAVR™ TAVR system.
Shares have been as much as 1.69% higher on the ASX to an intraday high of A$24.10.
About Anteris
Anteris Technologies is a structural heart company that delivers clinically superior and durable solutions through better science and better design.
Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.
Anteris’ DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.
The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of the DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.